Rimonabant
Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)
Sanofi · Phase 3 · Completed · Enrollment 1507
| Arm | Nausea | Vomiting | Diarrhea | Discontinuation | Deaths |
|---|---|---|---|---|---|
| Registry arm not named | n/r | n/r | n/r | n/r | n/r |
A count stays a count. This page does not turn a count into a percent.